Literature DB >> 1359995

Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype.

J Underhill1, P Donaldson, G Bray, D Doherty, B Portmann, R Williams.   

Abstract

In studies to date seeking associations between human leukocyte antigens (HLA) and primary biliary cirrhosis, no class I association but several different class II associations have been described. The aims of this study were to reassess the DR associations in primary biliary cirrhosis and to examine for the first time the role of DQB. DRB genotypes were determined on standard Taq1 restriction-fragment-length polymorphism analysis in 159 white northern European patients with the disease and 162 racially matched local controls. Polymerase chain reaction gene amplification and sequence-specific oligonucleotide analysis were used to determine DQB genotypes in 89 patients and 181 controls. An increased frequency of human leukocyte antigen DR8 was observed in the patient group (11% vs 4%; relative risk = 3.3; p < 0.01). Although we saw an increased frequency of the DQB1*0402 allele (11% vs. 3%; relative risk = 3.5; p < 0.025), this was not significant after correction for multiple testing. The strongest association was with the two-locus haplotype DR8-DQB1*0402 (11% vs. 2.2%; relative risk 5.5; p < 0.001). The DRB data reported here confirm the findings of previous studies, although the described association with DR8 is considerably weaker. The weak genetic contribution of human leukocyte antigen in the susceptibility to primary biliary cirrhosis is in contrast to its role in other autoimmune liver diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359995     DOI: 10.1002/hep.1840160616

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

Review 1.  Pathogenesis of primary biliary cirrhosis.

Authors:  David E J Jones
Journal:  Gut       Date:  2007-07-19       Impact factor: 23.059

Review 2.  Genetics and genomics of primary biliary cirrhosis.

Authors:  Brian D Juran; Konstantinos N Lazaridis
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

Review 3.  Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving.

Authors:  Pietro Invernizzi
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

4.  Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant.

Authors:  Jennifer E Guy; Peiqing Qian; Jeffrey A Lowell; Marion G Peters
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

5.  T cell responses to the putative dominant autoepitope in primary biliary cirrhosis (PBC).

Authors:  J M Palmer; A G Diamond; S J Yeaman; M F Bassendine; D E Jones
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

6.  A Case of Frontal Fibrosing Alopecia in a Patient with Primary Biliary Cirrhosis and Polymyalgia Rheumatica.

Authors:  Ariana N Eginli; Courtney W Bagayoko; Amy J McMichael
Journal:  Skin Appendage Disord       Date:  2016-09-10

Review 7.  Prevalence and pattern of familial disease in primary biliary cirrhosis.

Authors:  A M Brind; G P Bray; B C Portmann; R Williams
Journal:  Gut       Date:  1995-04       Impact factor: 23.059

8.  HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility.

Authors:  P Donaldson; K Agarwal; A Craggs; W Craig; O James; D Jones
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

9.  Familial clustering and genetic background of primary biliary cirrhosis in Japan.

Authors:  Masatoshi Yanagisawa; Hitoshi Takagi; Hitomi Takahashi; Masahiro Uehara; Toshiyuki Otsuka; Kazuhisa Yuasa; Kenichi Hosonuma; Masatomo Mori
Journal:  Dig Dis Sci       Date:  2009-12-11       Impact factor: 3.199

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.